MDMB-CHMINACA

MDMB-CHMINACA
Legal status
Legal status	CA: Schedule II; DE: NpSG (Industrial and scientific use only); UK: Class B; Illegal in Singapore and Switzerland;
Identifiers
	IUPAC name Methyl (2S)-2-{[1-(cyclohexylmethyl)-1H-indazol-3-yl]formamido}-3,3-dimethylbutanoate;
CAS Number	1185888-32-7;
PubChem CID	121491808;
ChemSpider	32055574;
UNII	Z6EXBVG316;
CompTox Dashboard (EPA)	DTXSID001010034 ;
Chemical and physical data
Formula	C22H31N3O3
Molar mass	385.508 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC(C)(C)[C@@H](C(=O)OC)NC(=O)C1=NN(C2=CC=CC=C21)CC3CCCCC3;
	InChI InChI=1S/C22H31N3O3/c1-22(2,3)19(21(27)28-4)23-20(26)18-16-12-8-9-13-17(16)25(24-18)14-15-10-6-5-7-11-15/h8-9,12-13,15,19H,5-7,10-11,14H2,1-4H3,(H,23,26)/t19-/m1/s1; Key:DGQMLBSSRFFINY-LJQANCHMSA-N;

MDMB-CHMINACA (also known as MDMB(N)-CHM) is an indazole-based synthetic cannabinoid that acts as a potent agonist of the CB₁ receptor, and has been sold online as a designer drug. It was invented by Pfizer in 2008, and is one of the most potent cannabinoid agonists known, with a binding affinity of 0.0944 nM at CB₁, and an EC₅₀ of 0.330 nM. It is closely related to MDMB-FUBINACA, which caused at least 1000 hospitalizations and 40 deaths in Russia as consequence of intoxication.

Legal status

Legal status	CA: Schedule II DE: NpSG (Industrial and scientific use only) UK: Class B Illegal in Singapore and Switzerland
Identifiers
IUPAC name Methyl (2S)-2-{[1-(cyclohexylmethyl)-1H-indazol-3-yl]formamido}-3,3-dimethylbutanoate
CAS Number	1185888-32-7
PubChem CID	121491808
ChemSpider	32055574
UNII	Z6EXBVG316
CompTox Dashboard (EPA)	DTXSID001010034
Chemical and physical data
Formula	C₂₂H₃₁N₃O₃
Molar mass	385.508 g·mol⁻¹
3D model (JSmol)	Interactive image
SMILES CC(C)(C)[C@@H](C(=O)OC)NC(=O)C1=NN(C2=CC=CC=C21)CC3CCCCC3
InChI InChI=1S/C22H31N3O3/c1-22(2,3)19(21(27)28-4)23-20(26)18-16-12-8-9-13-17(16)25(24-18)14-15-10-6-5-7-11-15/h8-9,12-13,15,19H,5-7,10-11,14H2,1-4H3,(H,23,26)/t19-/m1/s1 Key:DGQMLBSSRFFINY-LJQANCHMSA-N